TY  - JOUR
T1  - Üriner İnkontinans Medikal Tedavisi
TT  - Üriner İnkontinans Medikal Tedavisi
AU  - Bostancı, Mehmet Sühha
AU  - Özden, Selçuk
AU  - Ünal, Orhan
AU  - Cevrioğlu, Arif Serhan
AU  - Akdemir, Nermin
PY  - 2015
DA  - December
JF  - Journal of Human Rhythm
PB  - Ramazan AKDEMİR
WT  - DergiPark
SN  - 2149-455X
SP  - 83
EP  - 89
VL  - 1
IS  - 3
LA  - tr
AB  - Üriner inkontinans istemsiz idrar kaçırma olarak tanımlanır. Her yaş grubundan kadını etkileyebilen bu durum hastanın günlük yaşamında ciddi sıkıntılar meydana getirmektedir. Üriner inkontinans, stres üriner inkontinans, urge üriner inkontinans,miks üriner inkontinans ve aşırı aktif mesane olmak üzere alt gruplara ayrılır. Üriner inkontinans insidansı yaşlabirlikte artar ve stres üriner inkontinans genç kadınlarda daha sık görülür. Bu çalışma bu konuda son uluslararası literatür verileri karşılaştırılarak yapılmıştır. Bu yazının amacı üriner inkontinans medikal tedavisi hakkında genel bir bakış vermektir.
KW  - xx
N2  - Urinary incontinence is defi ned as involuntary leakage of urine. This situation may effect all age groups women and constitute serious problems that may affect the patient's daily life. Urinary incontinence is divided into sub-groups, including stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence and overactive bladder. The incidence of urinary incontinence increases with age and while stress urinary incontinence is more common in younger women. The study was conducted by comparing the data of the recent international literature on this topic. The purpose of this paper is to give an overview on the pharmacotherapy of urinary incontinence
CR  - Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of
CR  - lower urinary tract function. Report from the standardisation committee of
CR  - the International Continence Society. Neurourol Urodynam 2002;21:167–
CR  - Rortveit G, Hunskaar S. Urinary incontinence and age at the first and last
CR  - delivery: the Norwegian HUNT/EPINCONT study. Am J Obstet Gynecol
CR  - ;195(2):433Y438.
CR  - Urinary incontinence in women: the management of urinary incontinence in
CR  - women. National Collaborating Centre for Women’s and Children’s Health.
CR  - Royal College of Obstetricians and Gynaecologists, September 2013.
CR  - Thüroff JW, Abrams P, Andersson KE, et al. EAU guidelines on urinary
CR  - incontinence. Eur Urol 2011;59(3):387-400.
CR  - McGrother CW, Donaldson MM, Hayward T, et al. Urinary storage
CR  - symptoms and comorbidities: a prospective population cohort study in
CR  - middle-aged and older women. Age and Ageing 2006;35(1):16–24.
CR  - Minassian VA, Drutz HP, Al-Badr A. Urinary incontinence as a worldwide
CR  - problem. International Journal of Gynaecology and Obstetrics
CR  - ;82(3):327–38.
CR  - Shamliyan T,Wyman JF, Ramakrishnan R, et al. Benefits and harms of
CR  - pharmacologic treatment for urinary incontinence in women: a systematic
CR  - review. Ann Intern Med 2012;156(12):861-874.
CR  - Chapple CR, Khullar V, Gabriel Z, et al. The effects of antimuscarinic
CR  - treatments in overactive bladder: an update of a systematic review and
CR  - meta-analysis. Eur Urol 2008;54:543Y562.
CR  - Cipullo LM, Zullo F, Cosimato C, Di Spiezio Sardo A, Troisi J, Guida M.
CR  - Pharmacological treatment of urinary incontinence.Female Pelvic Med
CR  - Reconstr Surg. 2014 Jul-Aug;20(4):185-202.
CR  - Cipullo LM, Cosimato C, Filippelli A, Conti V, Izzo V, Zullo F, Guida
CR  - M.Pharmacological approach to overactive bladder and urge urinary
CR  - incontinence in women: an overview.Eur J Obstet Gynecol Reprod Biol.
CR  - Mar;174:27-34.
CR  - Cardozo L, Hebdorfer E, Milani R, et al. Solifenacin in the treatment of
CR  - urgency and other symptoms of overactive bladder; results from a
CR  - randomised, doubleblind, placebo-controlled, rising dose trial. BJU Int
CR  - ;102:1120–7.
CR  - Haab F, Cardozo L, Chapple C, Ridder AM, Solifenacin Study Group.
CR  - Long-term open label solifenacin treatment associated with persistence
CR  - with therapy in patients with overactive bladder syndrome. Eur Urol
CR  - ;47:376–84.
CR  - Cardozo L, Dixon A. Increased warning time with Darifenacin: a new
CR  - concept in the management of urinary urgency. J Urol 2005;173:1214–8.
CR  - Siddighi S, Chuan S. Medicine used in urogynecology. In: Siddighi S,
CR  - Hardesty JS, eds. Urogynecology and Female Pelvic Reconstructive Surgery:
CR  - Just the Facts. New York, NY: McGraw-Hill-Medical Publishing Division;
CR  - Nilvebrant L, Andersson K-E, Gillberg P-G, Stahl M, Sparf B. Tolterodine—a
CR  - new bladder selective antimuscarinic agent. Eur J Pharmacol 1997;327:195–
CR  - Nilvebrant L, Halle´n B, Larsson G, et al. TolterodineVa new bladder selective
CR  - muscarinic receptor antagonist: preclinical pharmacological and clinical
CR  - data. Life Sci 1997;60(13-14):1129-1136.
CR  - Madhuvrata P, Cody JD, Ellis G, et al. Which anticholinergic drug for
CR  - overactive bladder symptoms in adults. Cochrane Database Syst Rev
CR  - ;1:CD005429.
CR  - Appell RA. Clinical efficacy and safety of tolterodine in the treatment of
CR  - overactive bladder: a poled analysis. Urology 1997;50:90–6.
CR  - Swift S, Garely A, Dimpfl T, Payne C, Tolterodine Study Group. A new
CR  - once daily formulation of tolterodine provides superior efficacy an is well
CR  - tolerated in women with overactive bladder. Int J Pelvic Floor Dysfunct
CR  - ;14(1):50–4.
CR  - Diokno AC, Appell RA, Sand PK, et al. Prospective, randomised, double blind
CR  - study of the efficacy and tolerability of the extended-release formulations
CR  - of oxybutynin and tolterodine for overactive bladder: results of the OPERA
CR  - trial. Mayo Clin Proc 2003;78(6):687–95.
CR  - Madersbacher H, Stohrer M, Richter R, Burgdorfer H, Hachen HJ, Murtz
CR  - G. Trospium chloride versus oxybutynin: a randomized, double-blind,
CR  - multicentre trial in the treatment of detrusor hyper-reflexia. Br J Urol
CR  - ;75:452– 6.
CR  - Osca JM, Martinez-Agullo E, Broseta E, et al. Trospium chloride versus
CR  - oxybutynin in the treatment of bladder neurological disorders: a double
CR  - blind randomized clinical trial [Abstract]. Br J Urol 1997;80(Suppl 2):12.
CR  - Alabaster VA. Discovery and development of selective M3 antagonists for
CR  - clinical use. Life Sci 1997;60(13-14):1053-1060
CR  - Haab F, Stewart L, Dwyer P. Darifenacin an M3 selective receptor
CR  - antagonist, is an effective and well-tolerated once-daily treatment for
CR  - overactive bladder. Eur Urol 2004 Apr;45(4):420–9.
CR  - Novara G, Galfano A, Secco S, et al. A systematic review and meta-analysis
CR  - of randomized controlled trials with antimuscarinic drugs for overactive
CR  - bladder. Eur Urol 2008;54:740–64.
CR  - Chapple CR. Darifenacin is well tolerated and provides significant
CR  - improvement in the symptoms of overactive bladder: a pooled analysis of
CR  - phase III studies. J Urol 2004;171(Suppl):130 [abstract 487].
CR  - Ginsberg D, Schneider T, Kelleher C, et al. Efficacy of fesoterodine
CR  - compared with extended-release tolterodine in men and women with
CR  - overactive bladder. BJU Int 2013;112:373–85.
CR  - Chapple CR, Van Kerrebroeck PE, Junemann KP, Wang JT, Brodsky M.
CR  - Comparison of Fesoterodine and tolterodine in patients with overactive
CR  - bladder. BJU Int 2008;102:1128–32.
CR  - Madhuvrata P, Cody JD, Ellis G, et al. Which anticholinergic drug for
CR  - overactive bladder symptoms in adults. Cochrane Database Syst Rev
CR  - ;1:CD005429.5-31
CR  - Andersson KE, Chapple CR, Cardozo L, et al. Pharmacological treatment of urinary incontinence. ICS guidelines 2009.In: 4th international consultation
CR  - on incontinence. Curr Opin Urol 2009;19:380–94.
CR  - Siddighi S, Hardesty JS, editors. Urogynecology and female pelvic
CR  - reconstructive surgery: just the facts. New York: McGraw-Hill – Medical
CR  - Publishing Division; 2006
CR  - Jumadilova Z, Varadharajan S, Girase P, Ollendorf DA. Retrospectiveevaluation of outcomes in patients with overactive bladder receiving
CR  - tolterodine versus oxybutynin. Am J Health Syst Pharm 2006;63:2357–64.
CR  - Robinson D, Cardozo L. New drug treatments for urinary incontinence.
CR  - Maturitas 2010;65:340–7.
CR  - Dmochowski RR, Sand PK, Zinner NR, et al. Comparative efficacy and safety
CR  - of transdermal oxybutynin and oral tolterodine versus placebo in previously
CR  - treated patients with urge and mixed urinary incontinence. Urology
CR  - ;62(2):237–42.
CR  - Staskin DR, Dmochowski RR, Sand PK, et al. Efficacy and safety of oxybutynin
CR  - chloride topical gel for overactive bladder: a randomised, double blind,
CR  - placebo controlled, multicentre study. J Urol 2009;181:1764–72.
CR  - Chapple CR, Arano P, Bosch JL, De Ridder D, Kramer AE, Ridder
CR  - AM. Solifenacin appears effective and well tolerated in patients with
CR  - symptomatic idiopathic detrusor overactivity in a placebo and tolterodine
CR  - controlled phase II dosefinding study. BJU Int 2004;93:71–7.
CR  - Robinson D, Cardozo L, Terpstra G, et al. A randomized double-blind
CR  - placebo-controlled multicentre study to explore the efficacy and safety of
CR  - tamsulosin and tolterodine in women with overactive bladder syndrome.
CR  - BJU Int 2007;100(4):840Y845.
CR  - Sanford M. Mirabegron: a review of its use in patients with overactive
CR  - bladder syndrome. Drugs 2013;73:1213–25.
CR  - Tyagi P, Tyagi V, Chancellor M. Mirabegron: a safety review. Expert Opin
CR  - Drug Saf 2011;10:287–94.
CR  - Caremel R, Loutochin O, Corcos J. What do we know and not know about
CR  - mirabegron, a novel b3 agonist, in the treatment of overactive bladder? Int
CR  - Urogynecol J. 2014 Feb;25(2):165-70.
CR  - Nitti VW, Auerbach S, Martin N, et al. Results of a randomized phase III
CR  - trial of mirabegron in patients with overactive bladder. J Urol 2012;S0022-
CR  - (12): 05216-05210
CR  - Chapple CR, Kaplan SA, Mitcheson D, et al. Randomized double-blind,
CR  - active-controlled phase 3 study to assess 12-month safety and efficacy of
CR  - mirabegron, a A(3)-adrenoceptor agonist, in overactive bladder. Eur Urol
CR  - ;63(2):296-305.
CR  - U.S. Food and Drug Administration. FDA News Release [FDA web site].
CR  - August 25, 2011. Available at: http://www.fda.gov/ News Events/
CR  - Newsroom/ Press Announcements/ ucm 269509 .htm. Accessed August
CR  - , 2012.
CR  - Allergan. Long term follow-up study of safety and efficacy of botulinum
CR  - toxin type A for the treatment of patients with idiopathic overactive bladder
CR  - with urinary incontinence. Last update January 17, 2012.
CR  - de Groat WC. A neurologic basis for the overactive bladder. Urology
CR  - ;50(6A Suppl):36Y52; discussion 53.
CR  - Chai TC, Gray ML, Steers WD. The incidence of a positive ice water test in
CR  - bladder outlet obstructed patients: evidence for bladder neural plasticity. J
CR  - Urol 1998;160(1):34. 3-7.
CR  - Lazzeri M, Spinelli M, Beneforti P, et al. Intravesical resiniferatoxin for the
CR  - treatment of detrusor hyperreflexia refractory to capsaicin in patients with
CR  - chronic spinal cord diseases. Scand J Urol Nephrol 1998;32(5):331.
CR  - Silva C, Ribeiro MJ, Cruz F. The effect of intravesical resiniferatoxin in
CR  - patients with idiopathic detrusor instability suggests that involuntary
CR  - detrusor contractions are triggered by C-fiber input. J Urol 2002;168(2):575.
CR  - Thor KB, Katofiasc MA. Effects of Duloxetine, a combined serotonin and
CR  - norepineephrine reuptake inhibitor, on central neural control of lower
CR  - urinary tract function in the chloralose-anesthetised female cat. J Pharmacol
CR  - Exp Ther 1995;274:1014–24.
CR  - Norton PA, Zinner NR, Yalcin I, Bump RC, Duloxetine Urinary Incontinence
CR  - Study Group. Duloxetine versus placebo in the treatment of stress urinary
CR  - incontinence. Am J Obstet Gynaecol 2002;187(1):40–8.
CR  - Millard R, Moore K, Yalcin I, Bump R. Duloxetine vs. placebo in the
CR  - treatment of stress urinary incontinence: a global phase III study. Neurourol
CR  - Urodynam 2003;22:482–3.
CR  - Baldessarini KJ. Drugs in the treatment of psychhiatric disorders. In: Gilman,
CR  - et al., editors. The pharmacological basis of theraputics. 7th ed. McMillan
CR  - Publishing Co.; 1985. p. 387–445.
CR  - Castleden CM, Duffin HM, Gulati RS. Double-blind study of imipramine
CR  - and placebo for incontinence due to bladder instability. Age Aging
CR  - ;15:299–303.
CR  - Saks EK, Arya LA. Pharmacologic management of urinary incontinence,
CR  - voiding dysfunction, and overactive bladder. Obstet Gynecol Clin North Am
CR  - ;36(3):493-507.
CR  - Cody JD, Jacobs ML, Richardson K, et al. Oestrogen therapy for urinary
CR  - incontinence in post-menopausal women. Cochrane Database Syst Rev
CR  - ;10:CD001405
UR  - https://dergipark.org.tr/tr/pub/johr/article/123737
L1  - https://dergipark.org.tr/tr/download/article-file/105557
ER  -